Garousi, J.; Ding, H.; von Witting, E.; Xu, T.; Vorobyeva, A.; Oroujeni, M.; Orlova, A.; Hober, S.; Gräslund, T.; Tolmachev, V.
Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. Pharmaceutics 2021, 13, 1847.
https://doi.org/10.3390/pharmaceutics13111847
AMA Style
Garousi J, Ding H, von Witting E, Xu T, Vorobyeva A, Oroujeni M, Orlova A, Hober S, Gräslund T, Tolmachev V.
Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. Pharmaceutics. 2021; 13(11):1847.
https://doi.org/10.3390/pharmaceutics13111847
Chicago/Turabian Style
Garousi, Javad, Haozhong Ding, Emma von Witting, Tianqi Xu, Anzhelika Vorobyeva, Maryam Oroujeni, Anna Orlova, Sophia Hober, Torbjörn Gräslund, and Vladimir Tolmachev.
2021. "Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein" Pharmaceutics 13, no. 11: 1847.
https://doi.org/10.3390/pharmaceutics13111847
APA Style
Garousi, J., Ding, H., von Witting, E., Xu, T., Vorobyeva, A., Oroujeni, M., Orlova, A., Hober, S., Gräslund, T., & Tolmachev, V.
(2021). Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. Pharmaceutics, 13(11), 1847.
https://doi.org/10.3390/pharmaceutics13111847